A comparison of methods of plasmapheresis for the treatment of late antibody mediated rejection in kidney transplant recipients

被引:2
|
作者
Caliskan, Yasar [1 ,2 ]
Mirioglu, Safak [2 ,3 ]
Dirim, Ahmet Burak [2 ]
Ozluk, Yasemin [4 ]
Yegit, Ozan [2 ]
Aksoy, Elif [2 ]
Safak, Seda [2 ]
Guller, Nurana [2 ]
Demir, Erol [2 ]
Artan, Ayse Serra [2 ]
Oto, Ozgur Akin [2 ]
Besisik, Sevgi [5 ]
Yazici, Halil [2 ]
Turkmen, Aydin [2 ]
Lentine, Krista L. [1 ]
机构
[1] St Louis Univ, Sch Med, Ctr Abdominal Transplantat, 3660 Vista Ave, St Louis, MO 63110 USA
[2] Istanbul Univ, Istanbul Sch Med, Div Nephrol, Istanbul, Turkey
[3] Bezmialem Vakif Univ, Div Nephrol, Sch Med, Istanbul, Turkey
[4] Istanbul Univ, Istanbul Sch Med, Dept Pathol, Istanbul, Turkey
[5] Istanbul Univ, Istanbul Sch Med, Div Hematol, Istanbul, Turkey
关键词
antibody mediated rejection; kidney transplantation; plasmapheresis; rejection; HUMORAL REJECTION; ALLOGRAFT-REJECTION; PLASMA-EXCHANGE; RITUXIMAB; IMMUNOADSORPTION; OUTCOMES; THERAPY; RESCUE;
D O I
10.1111/1744-9987.13937
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction We compared the outcomes associated with plasma exchange (PE), double filtration plasmapheresis (DFPP), or immunoadsorption (IA) in the treatment of late antibody mediated rejection (AMR). Methods Sixty-nine kidney transplantation (KTx) recipients with late AMR were retrospectively categorized according to management with PE (n = 30), DFPP (n = 22) or IA (n = 17). Allograft loss was compared across treatment groups by Kaplan-Meier analysis and Cox regression. Results Study groups were similar regarding age, sex, donor type, kidney function, donor specific antibodies, and post-KTx follow-up time. Five-year graft survival trended higher with IA (70.6%) compared to PE (36.7%) and DFPP (27.3%) (p = 0.06). In multivariate Cox regression, baseline eGFR (HR per ml/min/1.73 m(2) [95% CI]; 0.96 [0.94-0.99]), rituximab use (HR [95% CI]; 0.42 [0.21-0.84]), interstitial inflammation (i) (HR [95% CI]; 2.05 [1.13-3.69]), and transplant glomerulopathy (cg) (HR [95% CI]; 1.46 [1.13-1.87]) were associated with graft loss. Conclusion These results motivate the need for continued assessment of rituximab and plasmapheresis in larger studies.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 50 条
  • [31] Tocilizumab for treatment of antibody mediated rejection in kidney transplant patients
    Szabo, Eszter
    Marton, Adrienn
    Remport, Adam
    Torok, Szilard
    Patonai, Attila
    Piros, Laszlo
    Fintha, Attila
    Szijarto, Attila
    Wagner, Laszlo
    Cseprekal, Orsolya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2680 - I2680
  • [32] Incidence of Antibody Mediated Rejection in Living Kidney Transplant Recipients with Sensitizing History
    Kakuta, Y.
    Okumi, M.
    Kanzawa, T.
    Unagami, K.
    Ishida, H.
    Tanabe, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 844 - 845
  • [33] Soluble BAFF Levels are Associated with Antibody Mediated Rejection in Kidney Transplant Recipients
    Rodrigo, Emilio
    Irure, Juan
    Sango, Cristina
    Benito-Hernandez, Adalberto
    Gomez-Roman, Javier
    San Segundo, David
    Fernandez-Fresnedo, Gema
    Valero, Rosalia
    Carlos Ruiz, Juan
    Lopez-Hoyos, Marcos
    TRANSPLANTATION, 2018, 102 : S485 - S485
  • [34] Conversion to Belatacept in kidney Transplant Recipients with Chronic Antibody Mediated Rejection (CAMR)
    Moein, Mahmoudreza
    Gao, Shuqi
    Martin, Samuel
    Farkouh, Katie
    Li, Benson
    Ball, Angela
    Dvorai, Reut Hod
    Saidi, Reza
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (01) : S36 - S36
  • [35] A CLINICAL AUDIT OF KIDNEY TRANSPLANT RECIPIENTS WITH ANTIBODY MEDIATED REJECTION IN SOUTHERN TASMANIA
    Patel, B.
    Nejatian, A.
    Skeat, L.
    Kirkland, G.
    Jose, M.
    NEPHROLOGY, 2020, 25 : 79 - 79
  • [36] Antibody Mediated Rejection in Kidney Transplant Recipients: Outcomes at a Single Center.
    Kumar, Vineeta
    Khamash, Hasan
    Julian, B. A.
    Prendergast, M. B.
    Kew, C. E.
    Hauptfeld, V.
    Gaston, R. S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 417 - 417
  • [37] EFFECTIVE STRATEGY FOR CHRONIC ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS
    Park, Woo Yeong
    Park, Ha Yeon
    Yeo, Sang Mok
    Kang, Seong Sik
    Park, Sung Bae
    Jin, Kyubok
    Han, Seungyeup
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [38] Effectiveness of Rituximab and Intravenous Immunoglobulin for the Treatment of Chronic Antibody Mediated Rejection in Kidney Transplant Recipients.
    An, G.
    Chung, B.
    Park, C.
    Choi, B.
    Kim, Y.
    Yang, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 328 - 328
  • [39] Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients
    Sangermano, Maria
    Negrisolo, Susanna
    Antoniello, Benedetta
    Vadori, Marta
    Cozzi, Emanuele
    Benetti, Elisa
    HUMAN IMMUNOLOGY, 2024, 85 (05)
  • [40] USE OF TOCILIZUMAB IN THE TREATMENT OF CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
    Sangermano, Maria
    Negrisolo, Susanna
    Antoniello, Benedetta
    Carraro, Andrea
    Vadori, Marta
    Cuciz, Elisa
    Longo, Germana
    Vidal, Enrico
    Meneghesso, Davide
    Parolin, Mattia
    Cozzi, Emanuele
    Benetti, Elisa
    PEDIATRIC NEPHROLOGY, 2023, 38 : S52 - S53